Introduction: Russia’s Two Flagship Nootropic Peptides
Semax and Selank are two synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both achieving regulatory approval in Russia and several CIS countries for neurological and cognitive applications. They represent two distinct approaches to brain function optimization: Semax through neurotrophic factor modulation and melanocortin signaling, Selank through anxiolytic and immunomodulatory pathways via tuftsin-derived mechanisms.
Despite their shared origin in Russian peptide pharmacology, these compounds target fundamentally different receptor systems and neurochemical pathways. Semax is primarily a cognitive enhancer and neuroprotectant derived from ACTH(4-7), while Selank is primarily an anxiolytic and immunomodulator derived from the immunopeptide tuftsin. Understanding their differences is essential for researchers designing cognitive enhancement, neuroprotection, or anxiety-related research protocols.
This comprehensive comparison examines both peptides across their structural biology, receptor pharmacology, neurotransmitter effects, clinical evidence, safety profiles, and research applications, drawing on the substantial Russian-language literature that forms the primary evidence base for both compounds.
Structural Biology and Origins
Semax: ACTH Fragment Engineering
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide based on the ACTH(4-7) fragment (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro tripeptide extension. The ACTH(4-7) core was identified in the 1970s as the minimal ACTH fragment retaining nootropic activity without hormonal (adrenocorticotropic) effects. The Pro-Gly-Pro tail was engineered by Ashmarin and colleagues to increase metabolic stability and extend the biological half-life from minutes to several hours.
The molecular weight of Semax is approximately 813 Da. Its structure allows intranasal administration with CNS penetration, bypassing the blood-brain barrier through olfactory and trigeminal nerve pathways. This delivery route enables direct brain targeting with minimal systemic exposure, an important advantage for CNS research applications.
Semax was developed at the Institute of Molecular Genetics under the direction of Nikolai Myasoedov beginning in the 1980s and received Russian regulatory approval in 2011 as a nootropic drug. It is available in Russia as a 0.1% and 1% nasal spray solution.
Selank: Tuftsin-Based Anxiolytic Design
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide based on the endogenous immunopeptide tuftsin (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro stabilizing extension used in Semax. Tuftsin was identified by Najjar and colleagues in the 1970s as a natural immunostimulating peptide derived from the Fc region of IgG immunoglobulin. It promotes phagocytosis, natural killer cell activity, and immune system modulation.
The molecular weight of Selank is approximately 751 Da. Like Semax, it is administered intranasally and achieves CNS penetration through olfactory pathways. The tuftsin core provides immunomodulatory properties that distinguish Selank from purely nootropic compounds, while the Pro-Gly-Pro extension confers metabolic stability necessary for pharmacological utility.
Selank was developed at the same Institute of Molecular Genetics, also under Myasoedov’s direction, and received Russian regulatory approval as an anxiolytic and nootropic drug. It is available in Russia as a 0.15% nasal spray solution.
Structural Comparison
Both peptides share the Pro-Gly-Pro C-terminal extension — a deliberate engineering choice that provides enzymatic resistance and extends the in vivo half-life. This shared structural element explains their similar pharmacokinetic profiles (nasal absorption, CNS penetration, multi-hour duration). However, their core tetrapeptide sequences are completely different: ACTH(4-7) for Semax (melanocortin-derived) vs tuftsin for Selank (immunoglobulin-derived). This core difference drives their divergent pharmacological profiles.
Receptor Pharmacology and Signaling Pathways
Semax: Melanocortin and Neurotrophic Signaling
Semax interacts with the melanocortin system, though its exact receptor binding profile remains incompletely characterized. Unlike full-length ACTH, Semax does not significantly activate MC2R (the adrenal receptor) and therefore does not stimulate cortisol release. Evidence suggests interaction with MC4R and possibly MC3R in the brain, though the binding affinity is lower than full melanocortin agonists.
The most well-documented mechanism of Semax is the upregulation of brain-derived neurotrophic factor (BDNF). Dolotov et al. (2006) demonstrated that Semax increases BDNF mRNA expression in the rat hippocampus and cortex within hours of administration. BDNF is the primary neurotrophin supporting synaptic plasticity, long-term potentiation (LTP), and neuronal survival. This BDNF induction is considered the primary mechanism underlying Semax’s nootropic and neuroprotective effects.
Semax also modulates nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF), creating a broad neurotrophic environment. The neurotrophic signaling cascade involves TrkB receptor activation, PI3K/Akt pathway engagement, and CREB phosphorylation — the same molecular pathway activated by exercise and enriched environments, two of the most validated neuroprotective interventions.
Downstream neurotransmitter effects of Semax include:
Dopamine: Semax increases dopaminergic transmission in the striatum and prefrontal cortex. Eremin et al. (2005) showed altered dopamine metabolism gene expression after Semax administration, supporting enhanced executive function, motivation, and attention.
Serotonin: Modulation of serotonergic signaling contributes to mood-stabilizing effects. Semax affects 5-HT metabolism without the direct receptor agonism of SSRIs, suggesting a modulatory rather than pharmacological effect on serotonin systems.
Acetylcholine: Enhanced cholinergic transmission supports the memory-enhancing properties observed in behavioral studies. This effect may be secondary to BDNF-mediated synaptic plasticity enhancement.
Selank: GABAergic, Serotonergic, and Immune Signaling
Selank’s anxiolytic mechanism is primarily mediated through the GABAergic system. Selank enhances GABA receptor sensitivity and modulates GABA-benzodiazepine receptor complex function without directly binding the benzodiazepine site. This produces anxiolytic effects comparable to benzodiazepines but without sedation, tolerance development, or withdrawal risk — a critical advantage documented in Russian clinical studies.
Serotonergic modulation is another key pathway. Selank influences serotonin metabolism and 5-HT receptor expression, particularly in brain regions associated with anxiety and emotional regulation (amygdala, hippocampus, prefrontal cortex). Semenova et al. (2010) demonstrated that Selank normalized serotonin metabolism in anxious animal models, restoring physiological balance rather than pharmacologically overriding the system.
The immunomodulatory properties derived from the tuftsin core provide unique CNS-immune crossover effects. Selank modulates inflammatory cytokine expression in the brain, which is increasingly recognized as relevant to anxiety and depression through the neuroinflammation hypothesis of psychiatric disorders. Selank reduces pro-inflammatory cytokines (IL-6, TNF-?) while maintaining or enhancing anti-inflammatory cytokines (IL-10), creating a neuroprotective anti-inflammatory environment.
Selank also influences enkephalin metabolism, stabilizing the degradation of endogenous opioid peptides. This contributes to its anxiolytic and mildly analgesic effects without producing opioid-like euphoria, dependence, or respiratory depression.
BDNF modulation by Selank has been documented but is less pronounced than Semax. Selank may increase BDNF in specific brain regions, but this appears to be a secondary rather than primary mechanism, contrasting with Semax where BDNF induction is the dominant pathway.
Clinical Evidence and Approved Applications
Semax Clinical Data
Semax has been studied in multiple Russian clinical trials across several neurological indications:
Acute ischemic stroke: Multiple clinical studies have demonstrated neuroprotective effects when Semax is administered during acute stroke. Gusev et al. (1997) published data showing improved neurological recovery and reduced infarct volume with intranasal Semax administration alongside standard stroke therapy. The 1% formulation (higher concentration) is specifically indicated for stroke and serious neurological conditions in Russian clinical practice.
Cognitive enhancement in healthy subjects: The 0.1% formulation is approved for cognitive enhancement in healthy adults. Clinical studies have shown improvements in attention, working memory, and learning capacity. Behavioral paradigms demonstrate enhanced performance on attention tasks, verbal fluency, and memory consolidation.
Optic nerve disease: Semax has been studied for glaucoma and optic nerve atrophy, with clinical evidence suggesting neuroprotective effects on retinal ganglion cells — consistent with its BDNF-mediated mechanism, as BDNF is critical for retinal neuron survival.
ADHD: Preliminary Russian clinical data suggests benefits in attention deficit disorders, consistent with Semax’s dopaminergic enhancement in prefrontal circuits.
The limitation of Semax clinical evidence is that the majority of studies are published in Russian-language journals and have not been replicated in Western clinical trial frameworks. While the volume of Russian clinical data is substantial, it does not meet the Phase III randomized controlled trial standard of Western regulatory agencies.
Selank Clinical Data
Selank’s clinical evidence base is similarly rooted in Russian research:
Generalized anxiety disorder (GAD): Selank’s primary approved indication in Russia is for anxiety disorders. Clinical trials have demonstrated anxiolytic efficacy comparable to benzodiazepines (specifically medazepam) without the sedation, cognitive impairment, muscle relaxation, or dependence risk associated with benzodiazepines. Zozulya et al. (2008) published comparative data showing similar anxiolytic response rates but superior cognitive preservation with Selank vs benzodiazepines.
Adjustment disorders with anxiety: Clinical studies in patients with stress-related anxiety disorders have shown Selank reduces both subjective anxiety and objective physiological stress markers (heart rate variability, cortisol).
Immunomodulation: Clinical studies have explored Selank’s immune-enhancing properties in immunocompromised patients and those with chronic infections, consistent with the tuftsin-derived immunostimulatory mechanism.
Cognitive effects: While Selank has nootropic approval, its cognitive effects are considered secondary to its anxiolytic properties. The cognitive improvement observed may be partly attributable to anxiety reduction — anxious individuals perform better cognitively when anxiety is relieved. Direct nootropic potency is considered less than Semax.
Side Effect Profiles and Safety
Semax Safety
Semax has an excellent safety profile based on decades of Russian clinical use and research. Documented characteristics include:
No significant adverse effects reported in clinical studies at approved doses (0.1% and 1% formulations). No hormonal disruption — despite ACTH derivation, Semax does not stimulate cortisol release. No sedation or psychomotor impairment. No tolerance or dependence with chronic use. No withdrawal syndrome upon discontinuation. No hepatotoxicity or renal toxicity documented. Intranasal administration avoids first-pass metabolism and associated GI side effects.
Reported mild effects include occasional transient nasal irritation and, at higher doses, mild stimulatory effects that may affect sleep if administered late in the day. The therapeutic window is wide, with no documented cases of serious adverse events in the published literature.
Selank Safety
Selank’s safety profile is similarly favorable:
No sedation (unlike benzodiazepines). No cognitive impairment (unlike benzodiazepines). No muscle relaxation (unlike benzodiazepines). No dependence or tolerance development with chronic use. No withdrawal syndrome — a critical advantage over benzodiazepine anxiolytics. No hepatotoxicity. No significant drug interactions documented.
The absence of benzodiazepine-type side effects is the central safety advantage of Selank as an anxiolytic. Benzodiazepine dependence is a major clinical problem, with withdrawal seizures representing a life-threatening risk. Selank provides anxiolysis through a completely different mechanism that avoids this liability.
Neurotransmitter Effects Comparison
| Neurotransmitter System | Semax | Selank |
|---|---|---|
| Dopamine | Strong enhancement (striatum, PFC) | Mild modulation |
| Serotonin | Moderate modulation | Strong modulation (metabolism normalization) |
| GABA | Minimal direct effect | Strong enhancement (receptor sensitization) |
| Acetylcholine | Enhanced transmission | Mild modulation |
| BDNF | Strong upregulation (primary mechanism) | Moderate upregulation (secondary) |
| NGF | Enhanced expression | Less characterized |
| Enkephalins | Minimal effect | Stabilization (reduced degradation) |
| Inflammatory Cytokines | Mild anti-inflammatory | Strong anti-inflammatory (tuftsin-derived) |
Research Applications: Choosing Between Semax and Selank
Choose Semax For:
Cognitive performance research: Semax’s dopaminergic enhancement and BDNF upregulation make it the primary choice for attention, learning, and memory research. The dopamine effects support executive function, motivation, and focus — the cognitive domains most relevant to “nootropic” applications.
Neuroprotection studies: Semax’s robust BDNF/NGF/GDNF neurotrophic profile makes it the stronger candidate for neuroprotection research, including models of stroke, neurodegenerative disease, and traumatic brain injury. The clinical stroke data from Russian trials supports this application.
ADHD-related research: Dopaminergic enhancement without stimulant-class side effects positions Semax as a research tool for attention deficit models.
Neuroplasticity investigations: BDNF-mediated synaptic plasticity enhancement makes Semax relevant for research on learning, memory consolidation, and neural circuit remodeling.
Choose Selank For:
Anxiety research: Selank is the clear choice for anxiety-related studies. Its GABAergic and serotonergic modulation provides anxiolysis without sedation, tolerance, or dependence — advantages over every other anxiolytic drug class.
Neuroimmunology: The tuftsin-derived immunomodulatory properties create a unique neuro-immune research tool. For studies exploring the relationship between neuroinflammation and mood/cognition, Selank offers mechanism-specific intervention.
Stress resilience: Selank’s ability to normalize stress-related neurochemical disruptions makes it valuable for chronic stress models and resilience research.
Benzodiazepine alternative research: For researchers studying anxiolytic mechanisms or seeking non-benzodiazepine tools for anxiety protocols, Selank provides a validated alternative with clinical evidence of comparable efficacy without the dependence liability.
Combining Semax and Selank
Because Semax and Selank operate through non-overlapping receptor systems (melanocortin/neurotrophic vs GABAergic/immunomodulatory), they can be combined in research protocols for complementary effects. A combination protocol targets both cognitive enhancement (Semax) and anxiety reduction (Selank) simultaneously, addressing the common clinical observation that anxiety impairs cognitive performance.
Russian clinical practice sometimes combines both peptides, alternating morning (Semax for daytime cognitive performance) and evening (Selank for anxiety reduction and sleep quality) administrations. This chronopharmacological approach leverages the distinct profiles of each compound for 24-hour neurological support.
Detailed Comparison Table
| Parameter | Semax | Selank |
|---|---|---|
| Core Peptide | ACTH(4-7) — melanocortin | Tuftsin — immunoglobulin |
| Molecular Weight | ~813 Da | ~751 Da |
| Primary Action | Nootropic / Neuroprotective | Anxiolytic / Immunomodulatory |
| Key Mechanism | BDNF upregulation + dopamine enhancement | GABA sensitization + serotonin modulation |
| Administration | Intranasal (0.1% or 1%) | Intranasal (0.15%) |
| Regulatory Status | Approved in Russia | Approved in Russia |
| Cognitive Enhancement | Strong (primary effect) | Moderate (secondary to anxiolysis) |
| Anxiolytic Effect | Mild | Strong (primary effect) |
| Neuroprotection | Strong (BDNF/NGF/GDNF) | Moderate (anti-inflammatory) |
| Immunomodulation | Minimal | Strong (tuftsin-derived) |
| Sedation Risk | None (mildly stimulating) | None (non-sedating anxiolytic) |
| Dependence Risk | None | None |
| Cortisol Effect | None (despite ACTH derivation) | Reduces stress-induced cortisol |
| Best Time of Day | Morning/daytime | Any time (no sedation) |
| Combinable | Yes (non-overlapping pathways) | Yes (non-overlapping pathways) |
Practical Considerations for Researchers
Sourcing and Quality
Both Semax and Selank are available as research peptides from suppliers like Proxiva Labs. Quality verification through HPLC and mass spectrometry is essential, as the intranasal route requires high purity. Research-grade formulations typically come as lyophilized powders requiring reconstitution with bacteriostatic water or sterile saline for nasal administration.
Dosing Considerations
In Russian clinical practice, Semax 0.1% is typically administered as 2-3 drops per nostril, 2-3 times daily (approximately 200-600 mcg per dose). The 1% formulation is reserved for serious neurological conditions. Selank 0.15% follows similar intranasal dosing protocols, typically 2-3 drops per nostril, 2-3 times daily.
Research protocols vary widely. Some investigators use subcutaneous administration for more controlled dosing, though the clinical evidence base is built on intranasal delivery. Stability after reconstitution is typically 2-4 weeks under refrigeration.
Duration of Effects and Cycling
Neither compound requires cycling in the traditional sense — no HPG axis suppression or receptor downregulation has been documented with chronic use. Russian prescribing guidelines suggest 10-14 day treatment courses with breaks between courses, but this appears to be convention rather than safety-driven necessity. No tolerance or tachyphylaxis has been documented for either compound in published clinical literature.
Conclusion
Semax and Selank represent two complementary approaches to brain function optimization from the same Russian peptide research tradition. Semax excels as a cognitive enhancer and neuroprotectant through BDNF upregulation and dopaminergic modulation — it is the choice for attention, memory, and neural protection research. Selank excels as a non-sedating, non-addictive anxiolytic with unique immunomodulatory properties through GABAergic sensitization and tuftsin-derived immune signaling — it is the choice for anxiety, stress, and neuroimmunology research.
Their non-overlapping mechanisms make combination protocols feasible, and their exceptional safety profiles (no hormonal disruption, no dependence, no hepatotoxicity, no sedation) position both compounds as valuable tools for cognitive and neurological research programs. As Western interest in these peptides grows, researchers benefit from the extensive (if largely Russian-language) clinical evidence base accumulated over three decades of development and clinical use.
Explore Semax and other research peptides at Proxiva Labs.
References
- Ashmarin IP, et al. Regulatory peptides in cognitive processes. Neurosci Behav Physiol. 2007;37(8):845-852.
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.
- Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
- Gusev EI, et al. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(2):35-38.
- Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
- Semenova TP, et al. Selank and its metabolic fragment reverse the inhibitory effect of GABA on the release of brain serotonin in vitro. Dokl Biol Sci. 2010;433:252-254.
- Kozlovskii II, et al. The anxiolytic action of Selank. Eksp Klin Farmakol. 2003;66(4):5-8.
- Levitskaya NG, et al. Neuroprotective effects of Semax in acute and chronic cerebral ischemia models. Neurosci Behav Physiol. 2008;38(6):629-635.
- Myasoedov NF, et al. Mechanisms of action of peptide regulatory drugs. Vestn Ross Akad Nauk. 2011;81(3):34-37.
- Narkevich VB, et al. Effects of Selank on dopamine and serotonin metabolism in the rat striatum. Bull Exp Biol Med. 2008;145(6):665-667.
This article is for educational and research purposes only. Not intended as medical advice. All compounds discussed are for laboratory research use. Visit Proxiva Labs for verified research peptides.